Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
86.30
-1.54 (-1.75%)
At close: Mar 6, 2026, 4:00 PM EST
87.99
+1.69 (1.96%)
After-hours: Mar 6, 2026, 7:33 PM EST
Mirum Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 521.31 | 336.89 | 186.37 | 77.06 | 19.14 | Upgrade
|
| Revenue Growth (YoY) | 54.74% | 80.76% | 141.85% | 302.67% | - | Upgrade
|
| Cost of Revenue | 100.24 | 81.64 | 47.04 | 12.37 | 1.9 | Upgrade
|
| Gross Profit | 421.07 | 255.25 | 139.34 | 64.69 | 17.24 | Upgrade
|
| Selling, General & Admin | 257.03 | 202.22 | 145.88 | 89.07 | 59.22 | Upgrade
|
| Research & Development | 186.18 | 140.63 | 102.61 | 106.84 | 131.43 | Upgrade
|
| Operating Expenses | 443.21 | 342.85 | 248.49 | 195.91 | 190.65 | Upgrade
|
| Operating Income | -22.14 | -87.61 | -109.15 | -131.22 | -173.41 | Upgrade
|
| Interest Expense | -14.39 | -14.31 | -15.11 | -15.98 | -17.59 | Upgrade
|
| Interest & Investment Income | 12.73 | 13.79 | 13.74 | 3.86 | 0.37 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.7 | 1.2 | -1.8 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 1.67 | 0.01 | -1.02 | 1.27 | 106.69 | Upgrade
|
| EBT Excluding Unusual Items | -21.43 | -86.91 | -113.35 | -142.07 | -83.95 | Upgrade
|
| Other Unusual Items | - | - | -49.08 | - | - | Upgrade
|
| Pretax Income | -21.43 | -86.91 | -162.42 | -142.07 | -83.95 | Upgrade
|
| Income Tax Expense | 1.94 | 1.03 | 0.99 | -6.41 | 0.04 | Upgrade
|
| Net Income | -23.36 | -87.94 | -163.42 | -135.67 | -83.99 | Upgrade
|
| Net Income to Common | -23.36 | -87.94 | -163.42 | -135.67 | -83.99 | Upgrade
|
| Shares Outstanding (Basic) | 50 | 48 | 41 | 34 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 50 | 48 | 41 | 34 | 30 | Upgrade
|
| Shares Change (YoY) | 5.63% | 16.23% | 20.31% | 12.07% | 20.08% | Upgrade
|
| EPS (Basic) | -0.47 | -1.85 | -4.00 | -4.01 | -2.77 | Upgrade
|
| EPS (Diluted) | -0.47 | -1.85 | -4.00 | -4.02 | -2.77 | Upgrade
|
| Free Cash Flow | 54.87 | 9.33 | -71.05 | -120.41 | -132.78 | Upgrade
|
| Free Cash Flow Per Share | 1.09 | 0.20 | -1.74 | -3.54 | -4.38 | Upgrade
|
| Gross Margin | 80.77% | 75.77% | 74.76% | 83.94% | 90.06% | Upgrade
|
| Operating Margin | -4.25% | -26.00% | -58.57% | -170.28% | -906.12% | Upgrade
|
| Profit Margin | -4.48% | -26.10% | -87.68% | -176.05% | -438.86% | Upgrade
|
| Free Cash Flow Margin | 10.53% | 2.77% | -38.12% | -156.26% | -693.81% | Upgrade
|
| EBITDA | 2.11 | -63.98 | -98.33 | -127.98 | -172.82 | Upgrade
|
| EBITDA Margin | 0.40% | -18.99% | -52.76% | -166.08% | - | Upgrade
|
| D&A For EBITDA | 24.24 | 23.63 | 10.83 | 3.24 | 0.6 | Upgrade
|
| EBIT | -22.14 | -87.61 | -109.15 | -131.22 | -173.41 | Upgrade
|
| EBIT Margin | -4.25% | -26.00% | -58.57% | -170.28% | - | Upgrade
|
| Revenue as Reported | 521.31 | 336.89 | 186.37 | 77.06 | 19.14 | Upgrade
|
| Advertising Expenses | 10.9 | 11.5 | 6.3 | 4 | 9.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.